Training to build resilience during the COVID-19 pandemic
Building Resilience During the COVID-19 Pandemic: a Randomized Controlled Trial
This study is testing whether a new Resilience Training program can help people in Austria who are struggling with mental health issues from the COVID-19 pandemic feel better compared to a relaxation technique.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 192 (estimated) |
| Ages | 18 Years to 70 Years |
| Sex | All |
| Sponsor | Medical University Innsbruck Academic / other |
| Locations | 1 site (Innsbruck, Tirol) |
| Trial ID | NCT05802875 on ClinicalTrials.gov |
What this trial studies
This clinical trial tests the effectiveness of a Resilience Training program (RASMUS) compared to Progressive Muscle Relaxation (PMR) in improving resilience and reducing psychological distress among individuals experiencing mental health challenges due to the COVID-19 pandemic. The study involves 192 participants from the general population in Austria, who will be randomly assigned to either intervention group. Assessments will be conducted at the start, immediately after the intervention, and at a 6-month follow-up to evaluate both short-term and long-term effects. Additionally, brain imaging will be utilized to explore changes in brain structure and function associated with the interventions.
Who should consider this trial
Good fit: Ideal candidates are German-speaking individuals from the general population in Austria experiencing clinically relevant psychological distress.
Not a fit: Patients with psychiatric disorders or those currently receiving psychological therapy may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance mental resilience and reduce psychological distress in individuals affected by the COVID-19 pandemic.
How similar studies have performed: Other studies have shown promising results in resilience training, but this specific approach during the COVID-19 pandemic is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * GSI-T score (Mini-SCL) ≥63, * BRS score \<3, * fluent German speakers, * written informed consent. Exclusion Criteria: * Any psychiatric disorder according to the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) (verified by Mini International Neuropsychiatric Interview \[M.I.N.I.\] 7.0.2), a history of nicotine or caffeine dependence is acceptable, * currently engaged in any form of regular psychological therapy offered by psychologists and/or psychiatrists, * currently engaged in any form of (group) interventions from other disciplines (social work, pedagogy, coaching, alternative therapy etc.)
Where this trial is running
Innsbruck, Tirol
- Medical University Innsbruck — Innsbruck, Tirol, Austria (Recruiting)
Study contacts
- Principal investigator: Alex Hofer, Dr. — Medical University Innsbruck
- Study coordinator: Alex Hofer, Dr.
- Email: a.hofer@i-med.ac.at
- Phone: +4351250423669
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.